Pfizer (PFE) This fall Outcomes 2022

Vials of the Pfizer/BioNtech coronavirus disease (COVID-19) vaccine are displayed before being used at a mobile vaccine clinic in Valparaiso, Chile, on January 3, 2022.

Rodrigo Garrido | Reuters

Pfizer issued a sales guidance of $67 billion to $71 billion for 2023 on Tuesday, down from record 2022 results.

The drug company booked $100.3 billion for full-year 2022, an all-time high, driven by more than $50 billion in sales of Covid vaccines and antivirals.

related investment news

Pfizer expects sales for 2023 to fall by up to 33% compared to 2022 as the pandemic eases and demand for its Covid portfolio falls. The company expects $13.5 billion in 2023 Covid vaccine sales and $8 billion in revenue for Paxlovid.

Pfizer is forecasting earnings of between $3.25 and $3.45 per share for 2023, down 50% from its record $6.58 in 2022. The company reported net income of $31.4 billion in 2022, a 43% increase from 2021.

Pfizer’s stock fell 3% in premarket trading.

The drugmaker’s fourth-quarter results broadly met analysts’ expectations. The company reported net income of nearly $5 billion for the quarter, up 47% from the same period in 2021. It generated revenue of $24.3 billion for the quarter.

Here’s how the company performed versus Wall Street’s expectations for the fourth quarter, based on average analyst estimates compiled by Refinitiv:

  • Adjusted earnings per share: $1.14 versus $1.05 expected
  • Revenues: $24.3 billion versus $24.28 billion

CNBC Health & Science

Read CNBC’s latest global health coverage:

Comments are closed.